Thymosin Beta-4 Accelerates Wound Healing by Up to 61% in Rats

Thymosin beta-4 (Tβ4) applied topically or intraperitoneally to full-thickness wounds in rats accelerated skin regrowth by 42% at day 4 and up to 61% at day 7 compared to saline controls. Treated wounds also contracted at least 11% more than controls by day 7. The peptide increased collagen deposition and new blood vessel formation in the wound. In lab assays, thymosin beta-4 stimulated keratinocyte (skin cell) migration 2–3-fold at doses as low as 10 picograms — an extraordinarily small amount.

Researchers used a rat full-thickness wound model, applying thymosin beta-4 either topically to the wound or via intraperitoneal injection, with saline as a control. They measured wound reepithelialization (skin regrowth) and contraction at days 4 and 7. Collagen deposition and angiogenesis were assessed histologically. In parallel, keratinocyte migration was measured using a Boyden chamber assay with varying concentrations of thymosin beta-4.

This 1999 study was one of the first to demonstrate thymosin beta-4's wound healing potential with specific numbers. The fact that such tiny amounts of the peptide could dramatically accelerate skin regrowth, increase collagen production, and promote new blood vessel formation made it a landmark finding. It helped establish thymosin beta-4 as one of the most promising wound-healing peptides and spurred decades of subsequent research into its clinical applications.

This study is a foundational paper in the thymosin beta-4 research field. Published in 1999, it provided some of the first quantitative evidence that this peptide could be a potent wound-healing agent. It helped catalyze a wave of research into thymosin beta-4's mechanisms — including its roles in cell migration, angiogenesis, and inflammation modulation — that continues today. The peptide has since been investigated for corneal repair, cardiac regeneration, and chronic wound treatment.

This is an animal study in rats — wound healing in rodents differs from humans in important ways (rats heal partly by contraction, humans primarily by reepithelialization). The study used a relatively short observation period (7 days). No toxicity or long-term safety data were reported. The specific mechanisms by which thymosin beta-4 produces these effects were not fully elucidated in this study.